TNSN97191A1 - Dimesylate de cis-1-(3 ethoxyphenyl)-1-(4-phenyl-piperazine-1- yl)-4- methylcyclohexane, procede pour sa preparation et composition pharmaceutique. - Google Patents

Dimesylate de cis-1-(3 ethoxyphenyl)-1-(4-phenyl-piperazine-1- yl)-4- methylcyclohexane, procede pour sa preparation et composition pharmaceutique.

Info

Publication number
TNSN97191A1
TNSN97191A1 TNTNSN97191A TNSN97191A TNSN97191A1 TN SN97191 A1 TNSN97191 A1 TN SN97191A1 TN TNSN97191 A TNTNSN97191 A TN TNSN97191A TN SN97191 A TNSN97191 A TN SN97191A TN SN97191 A1 TNSN97191 A1 TN SN97191A1
Authority
TN
Tunisia
Prior art keywords
preparation
pharmaceutical composition
dimesylate
ethoxyphenyl
methylcyclohexane
Prior art date
Application number
TNTNSN97191A
Other languages
English (en)
Inventor
J M Allen Douglas
R Brostrom Lyle
S Kord Alireza
A Whipple Laurie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN97191A1 publication Critical patent/TNSN97191A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE LE COMPOSE DE FORMULE ...............ELLE CONCERNE EGALEMENT UNE COMPOSITION PHARMACEUTIQUE COMPRENANT LA FORME A DE CE COMPOSE ET UN PROCEDE POUR LA PREPARATION DE CETTE FORME A. APPLICATION : TRAITEMENT DE TROUBLES PHYSIOLOGIQUES ASSOCIES A UN EXCES DE NEUROPEPTIDE Y.
TNTNSN97191A 1996-11-26 1997-11-25 Dimesylate de cis-1-(3 ethoxyphenyl)-1-(4-phenyl-piperazine-1- yl)-4- methylcyclohexane, procede pour sa preparation et composition pharmaceutique. TNSN97191A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3181596P 1996-11-26 1996-11-26

Publications (1)

Publication Number Publication Date
TNSN97191A1 true TNSN97191A1 (fr) 2005-03-15

Family

ID=21861551

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97191A TNSN97191A1 (fr) 1996-11-26 1997-11-25 Dimesylate de cis-1-(3 ethoxyphenyl)-1-(4-phenyl-piperazine-1- yl)-4- methylcyclohexane, procede pour sa preparation et composition pharmaceutique.

Country Status (23)

Country Link
US (1) US5914329A (fr)
EP (1) EP0944611B1 (fr)
JP (1) JP3120861B2 (fr)
AP (1) AP9701148A0 (fr)
AR (1) AR010304A1 (fr)
AT (1) ATE257472T1 (fr)
AU (1) AU4792497A (fr)
BR (1) BR9713538A (fr)
CA (1) CA2272927C (fr)
DE (1) DE69727155T2 (fr)
DK (1) DK0944611T3 (fr)
ES (1) ES2213207T3 (fr)
GT (1) GT199700123A (fr)
HN (1) HN1997000154A (fr)
HR (1) HRP970640A2 (fr)
ID (1) ID18964A (fr)
MA (1) MA26450A1 (fr)
PA (1) PA8441701A1 (fr)
PE (1) PE17099A1 (fr)
PT (1) PT944611E (fr)
TN (1) TNSN97191A1 (fr)
WO (1) WO1998023603A1 (fr)
ZA (1) ZA9710587B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001232900A1 (en) * 2000-01-20 2001-07-31 Michael Amling Methods and compositions for control of bone formation via modulation of neuropeptide y activity
JP2005516001A (ja) 2001-12-05 2005-06-02 ベイラー カレッジ オブ メディスン 交感神経活動状態の調節による骨形成の制御のための方法及び組成物
WO2003057886A2 (fr) 2002-01-09 2003-07-17 Arexis Ab Detection de mutations
US20070254930A1 (en) * 2004-11-23 2007-11-01 Dong Wha Pharm. Ind. Co., Ltd. Oral Preparation Having Improved Bioavailability
AU2006235200A1 (en) * 2005-04-15 2006-10-19 Regenertech Pty Limited Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU692977B2 (en) * 1994-11-07 1998-06-18 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands

Also Published As

Publication number Publication date
MA26450A1 (fr) 2004-12-20
PE17099A1 (es) 1999-02-19
ES2213207T3 (es) 2004-08-16
PA8441701A1 (es) 2000-05-24
JP2000505110A (ja) 2000-04-25
DK0944611T3 (da) 2004-04-13
BR9713538A (fr) 2000-03-21
AU4792497A (en) 1998-06-22
ID18964A (id) 1998-05-28
GT199700123A (es) 1999-05-19
HN1997000154A (es) 1999-02-09
JP3120861B2 (ja) 2000-12-25
WO1998023603A1 (fr) 1998-06-04
DE69727155T2 (de) 2004-07-08
EP0944611A1 (fr) 1999-09-29
ZA9710587B (en) 1999-05-25
DE69727155D1 (de) 2004-02-12
ATE257472T1 (de) 2004-01-15
CA2272927A1 (fr) 1998-06-04
AR010304A1 (es) 2000-06-07
HRP970640A2 (en) 1998-10-31
AP9701148A0 (en) 1998-01-31
US5914329A (en) 1999-06-22
PT944611E (pt) 2004-04-30
EP0944611B1 (fr) 2004-01-07
CA2272927C (fr) 2003-02-04

Similar Documents

Publication Publication Date Title
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99147A1 (fr) Procede d'emulsification
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
TNSN00092A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98022A1 (fr) DERIVES DE N-HYDROXY-β-SULFONYLPROPIONAMIDE, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
TNSN98019A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN00231A1 (fr) Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant
TNSN99079A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98104A1 (fr) Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.